Enlivex Therapeutics announces peer-reviewed publication on Allocetra

Enlivex Therapeutics announced the peer-reviewed publication of clinical and exploratory data from a Phase Ib and a Phase IIa clinical trial in Frontiers in Immunology. The paper, entitled “Apoptotic cells for treatment of acute respiratory distress syndrome, ARDS, associated with COVID-19” describes a multicenter study that was published in collaboration with researchers at Hadassah-Hebrew University Medical Center, Barzilai Medical Center and Ziv Medical Center Israel. Key data and conclusions from the paper include: Allocetra-treated patients exhibited rapid resolution from their ARDS. Allocetra-treated patients had a mortality rate of 0% with complete recovery of 19/21 patients at the end of the study’s 28-day follow-up period, compared to a mortality rate of 3.8%-8.9% for age- and gender-severe COVID-19-matched patients, and 39%-55% for critical patients. Average duration of hospitalization post-administration of Allocetra for discharged patients was 5.6 days. All patients had elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that steadily decreased following AllocetraTM treatment. No serious related adverse events were reported with Allocetra treatment with an overall favorable safety profile.